Floatz logo

Brentuximab Vedotin

Folliculotropic Mycosis Fungoides

City of Hope Medical Centerantibody_drug_conjugatePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Folliculotropic Mycosis Fungoides cohort.

Asset / SponsorPhaseRating
Triamcinalone
Rochester Skin Lymphoma Medical Group, PLLC
Phase 2B
Mechlorethamine
Rochester Skin Lymphoma Medical Group, PLLC
Phase 2B
cc-5013
City of Hope Medical Center
Phase 1/2CCC
MOGAMULIZUMAB
City of Hope Medical Center
Phase 2CCC
Durvalumab
City of Hope Medical Center
Phase 1/2CCC

Same molecule, other indications

Brentuximab Vedotin is also rated in:

T-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
anaplastic large cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →